FDPS, farnesyl diphosphate synthase, 2224

N. diseases: 83; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4225262
Disease: POROKERATOSIS 9, MULTIPLE TYPES
POROKERATOSIS 9, MULTIPLE TYPES 		0.700 CausalMutation disease CLINVAR
CUI: C4225262
Disease: POROKERATOSIS 9, MULTIPLE TYPES
POROKERATOSIS 9, MULTIPLE TYPES 		0.700 Biomarker disease CTD_human
CUI: C0162839
Disease: Porokeratosis
Porokeratosis 		0.110 Biomarker disease HPO
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.100 Biomarker disease HPO
CUI: C0033774
Disease: Pruritus
Pruritus 		0.100 Biomarker phenotype HPO
CUI: C0349506
Disease: Photosensitivity of skin
Photosensitivity of skin 		0.100 Biomarker phenotype HPO
CUI: C0015468
Disease: Facial Pain
Facial Pain 		0.020 GeneticVariation phenotype BEFREE Facial Pain Scale Revised (FPS-R) and Face, Leg, Activity, Cry, Consolability (FLACC) scores were used to evaluate pain and anxiety before, during and after procedure. 28190665 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 Biomarker group BEFREE FPS-1 cells showed the same morphological and immunophenotypical characteristics as the primary tumor. 17094458 2006
CUI: C0334463
Disease: Malignant Fibrous Histiocytoma
Malignant Fibrous Histiocytoma 		0.010 Biomarker disease BEFREE FPS-1 cells might be useful for investigating biological behavior and developing new molecular targeting antitumor drugs for UPS with EGFR or COX-2 expression. 17094458 2006
CUI: C0029463
Disease: Osteosarcoma
Osteosarcoma 		0.010 Biomarker disease LHGDN Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. 18494934 2008
CUI: C0034067
Disease: Pulmonary Emphysema
Pulmonary Emphysema 		0.010 Biomarker disease BEFREE FPS-ZM1 administration significantly reversed emphysema in the lung of mice. 28148566 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.010 Biomarker phenotype BEFREE Farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway, was recently shown to play a role in cancer progression. 29337059 2018
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.010 Biomarker phenotype BEFREE FPPS expression of FPPS was induced by TGF-β1 and FPPS promoted cell invasion and EMT via the RhoA/Rock1 pathway. 29337059 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis 		0.060 Biomarker disease BEFREE FPS-ZM1 can rescue the negative effects of AGEs and provide a possible treatment for bone tissue regeneration in patients with diabetic osteoporosis. 30014569 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma 		0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.030 AlteredExpression disease BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 AlteredExpression group BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.050 AlteredExpression group BEFREE FDPS mRNA in patients with glioblastoma was associated with malignancy in three independent microarray data sets. 30333528 2018
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.020 Biomarker disease BEFREE Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells. 31725297 2019
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.020 Biomarker disease BEFREE Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells. 31725297 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.060 Biomarker group BEFREE A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting <i>Hs</i>FPPS, leading to downregulation of Ras prenylation and cell apoptosis. 31725297 2019
CUI: C3839507
Disease: Diminished ovarian reserve
Diminished ovarian reserve 		0.010 Biomarker disease BEFREE AFC: antral follicle count; BMI: body mass index; DOR: diminished ovarian reserve; E2: estradiol; FPS: follicular-phase stimulation; FSH: follicle stimulating hormone; GnRH: gonadotropin-releasing hormone; HCG: human chorionic gonadotropin; IRB: institutional review board; IVF: in vitro fertilization; LH: luteinizing hormone; LPS: luteal-phase stimulation; MII: metaphase II. 29564925 2018
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.030 GeneticVariation disease BEFREE Analysis of single nucleotide polymorphisms in the hFPPS gene and mRNA levels in autopsy-confirmed AD subjects was undertaken, and a genetic link between hFPPS and phosphorylated tau (P-Tau) levels in the human brain was identified. 24911527 2014